ADMA Biologics, Inc.

ADMA

US0008991046

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
6.55 ^USD	+1.71%		+4.47%	+44.91%

Apr. 02	ADMA Biologics, Inc. Announces Promotion of Kaitlin Kestenberg as Chief Operating Officer	CI
Mar. 26	HC Wainwright Adjusts ADMA Biologics Price Target to $7.50 From $6, Maintains Buy Rating	MT

ADMA Biologics, Inc. Revises Financial Guidance for the Years 2024 and 2025

February 28, 2024 at 04:16 pm EST

ADMA Biologics, Inc. revised financial guidance for the years 2024 and 2025. For the years 2024 and 2025, the company expects total revenue now to be more than $330 million and $380 million, respectively, increased from prior guidance of $320 million and $370 million, respectively.

Latest news about ADMA Biologics, Inc.

ADMA Biologics, Inc. Announces Promotion of Kaitlin Kestenberg as Chief Operating Officer	Apr. 02	CI
HC Wainwright Adjusts ADMA Biologics Price Target to $7.50 From $6, Maintains Buy Rating	Mar. 26	MT
Adma Biologics Insider Sold Shares Worth $2,803,741, According to a Recent SEC Filing	Mar. 20	MT
Adma Biologics, Inc. Announces FDA Approvals of Extended Room Temperature Storage Conditions for Asceniv & Bivigam	Mar. 11	CI
Mizuho Adjusts Price Target on ADMA Biologics to $10 From $9, Maintains Buy Rating	Mar. 01	MT
ADMA Biologics Q4 Net Loss Widens, Revenue Rises; Increases 2024, 2025 Revenue Outlook; Seeks Successor for Chief Financial Officer	Feb. 28	MT
ADMA Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Transcript : ADMA Biologics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (ADMA) ADMA BIOLOGICS Posts Q4 Revenue $73.9M, vs. Street Est of $73M	Feb. 28	MT
ADMA Biologics, Inc. Revises Financial Guidance for the Years 2024 and 2025	Feb. 28	CI
ADMA Biologics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
ADMA Biologics Implements ADMAlytics AI Program to Bolster Production	Feb. 21	MT
ADMA Biologics, Inc Successfully Implements Innovative AI Program, Named ADMAlytics	Feb. 21	CI
Mizuho Securities Raises Price Target on ADMA Biologics to $9 From $7, Maintains Buy Rating	Jan. 22	MT
HC Wainwright Adjusts Price Target on ADMA Biologics to $6 From $5, Maintains Buy Rating	Jan. 09	MT
ADMA Biologics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023, Fiscal Year 2024-2025	Jan. 08	CI
ADMA Biologics Taps $135 Million Credit Facility From Debt Refinancing	Dec. 18	MT
ADMA Biologics, Inc. Expands Credit Facility with Ares Capital Corporation	Dec. 18	CI
ADMA Biologics, Inc. Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management	Dec. 18	CI
ADMA Biologics, Inc. Announces FDA Approval for BIVIGAM in the Pediatric Patient Setting for Those 2 Years of Age and Older	Dec. 12	CI
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading	Nov. 16	MT
ADMA Biologics Obtains US FDA Approval for Plasma Collection Center in Maryland	Nov. 16	MT
ADMA Biologics, Inc. Receives FDA Approval for Its Tenth Plasma Collection Center, Located in Laurel, MD	Nov. 16	CI
ADMA Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Earnings Flash (ADMA) ADMA BIOLOGICS Posts Q3 Revenue $67.3M, vs. Street Est of $62.1M	Nov. 08	MT

Chart ADMA Biologics, Inc.

Duration

Period

More charts

Company Profile

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for ADMA Biologics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.55 USD

Average target price

8.375 USD

Spread / Average Target

+27.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
ADMA BIOLOGICS, INC.	+44.91%	1.52B
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals